Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psychiatric Genomics Inc.

www.psygenomics.com

Latest From Psychiatric Genomics Inc.

Broad gets $650m for psychiatric genomic research, hopes pharma joins effort

Philanthropist Ted Stanley made a multi-year $650m commitment to fund genomic research at the Eli and Edythe L Broad Institute in collaboration with scientists around the world that may generate biological pathways and molecules that could reignite pharmaceutical company interest in schizophrenia, bipolar disorder and other psychiatric conditions.

Cancer Neurology

Biocortech

Biocortech was established in November 2001 to commercialize the fruits of the founders' research into the underlying causes of treatment-resistant forms of CNS diseases such as depression and schizophrenia. The company's aim is to develop effective therapies for these and other diseases associated with the pre-frontal cortex of the brain, such as bipolar disorder and cognitive and sexual disorders.
BioPharmaceutical Europe

Avalon Pharmaceuticals Inc.

Avalon Pharmaceuticals Inc. hopes to harness the explosion of target information to identify promising drugs without having to rely first on finding new targets. It is employing its target-independent platform to look at the activities of compounds much earlier in the discovery process than conventional screening methods.
BioPharmaceutical Research and Development Strategies

Psychiatric Genomics Inc.

Psychiatric Genomics will use information generated by the Human Genome Project, along with gene expression, microarray and high-throughput technology to uncover the complex, multiple genetic factors implicated in mental illness. It will initially focus on schizophrenia, bipolar disorder and autism--underserved illnesses with strong evidence of a genetic component.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Psychiatric Genomics Inc.
  • Senior Management
  • Richard E Chipkin, PhD, CEO
    David A Theil, CFO
  • Contact Info
  • Psychiatric Genomics Inc.
    Phone: (301) 556-1300
    19 Firstfield Rd.
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register